BECOME A PARTICIPANT
Individuals who participate in our research studies are vital to the mission of PRISM. If you are interested in becoming a participant in one of our research studies,
learn more about the different opportunities below.
ALL STUDIES ARE CONDUCTED BY WASHINGTON STATE UNIVERSITY.
AVAILABLE STUDIES
ZONISAMIDE FOR THE TREATMENT OF ALCOHOL USE DISORDER IN THE ADDICTION NEUROCLINICAL ASSESSMENT FRAMEWORK (ZARRA)
Washington State University and The Community Health Association of Spokane (CHAS) are partnering to conduct a study evaluate the ability of a medication called zonisamide to decrease alcohol use among treatment-seeking adults with an alcohol use disorder.
​
Participants will be asked to take a medication (either zonisamide
or matching placebo) over a period of 14 weeks at a dosing schedule that is consistent with best practices for zonisamide. They will be asked to fill out questionnaires, watch educational modules, and complete a urinalysis during the study visits. Participation will involve three visits per week from weeks 1-6, one visit per week from weeks 7-14, and three visits total at weeks 18, 27, and 54.
​
Eligibility for this study includes being between the ages 18-65, having four or more standard drinks on four or more occasions in the prior 30 days, be non-pregnant or lactating, and currently seeking alcohol use disorder treatment. Participants may receive up to approximately $463 in virtual gift cards over the course of the study.
Location: Spokane, WA
Currently recruiting; anticipated end date July 2025
PHARMACEUTICALLY-ENHANCED REINFORCEMENT FOR REDUCED ALCOHOL AND SMOKING (PERRAS)
Washington State University is partnering with Recovery Centers, Oregon Recovery and Treatment Centers and Range Community Clinic to conduct a study to evaluate the ability of evidence based behavioral treatment, called contingency management, to decrease alcohol use and cigarette smoking among treatment-seeking smokers with an alcohol use disorder who have initiated varenicline (Chantix) for smoking cessation.
​
Participants will be asked take varenicline for a 12-week treatment period. They will be asked to watch educational modules, fill out questionnaires and complete a urinalysis during the study visits. Participation will involve three visits per week from weeks 1-14 and three visits total at weeks 18, 27, and 54.
​
Eligibility for this study includes ≥ 18 years of age, having four or more standard drinks on four or more occasions in the prior 30 days, and currently seeking alcohol use disorder and smoking cessation treatment. Participants may receive up to approximately $600 in virtual gift cards over the course of the study.
Location: Spokane, WA
Currently recruiting; anticipated end date March 2025
MANAGEMENT TO REDUCE HEAVY ALCOHOL DRINKING DAYS AMONG SMOKERS RECEIVING VARENICLINE TREATMENT (CM4HDS)
Washington State University and The Community Health Association of Spokane (CHAS) are partnering to conduct a study to evaluate the ability of a well-studied behavioral intervention method, called contingency management, to decrease alcohol use and cigarette smoking among treatment-seeking smokers with an alcohol use disorder who have initiated varenicline (Chantix) for smoking cessation.
​
Participants will be asked to use a phone application that monitors smoking and alcohol use. They will be asked to submit breathalyzer samples, complete saliva samples, and fill out questionnaires at study visits. Participation will involve weekly study visits for a 9-week treatment period.
​
Eligibility for this study includes ≥ 21 years of age, currently receiving varenicline treatment 6 weeks prior to study initiation, and currently seeking alcohol use disorder treatment. Participants may receive up to approximately $670 in virtual gift cards over the course of the study.
Location: Spokane, WA
Currently recruiting; anticipated end date July 1, 2025
